Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.
Gilead Sciences, Inc. (Nasdaq: GILD) is a biopharmaceutical company focused on medicines for HIV, viral hepatitis, COVID‑19, cancer and inflammation. The GILD news feed highlights how the company’s research, collaborations and policy decisions translate into clinical programs, regulatory milestones and access initiatives across these therapeutic areas.
Investors and healthcare observers following GILD news will see regular updates on Gilead’s HIV portfolio, including clinical trial readouts such as the Phase 3 ARTISTRY‑1 and ARTISTRY‑2 studies of an investigational single‑tablet regimen combining bictegravir and lenacapavir for virologically suppressed adults with HIV. News also covers developments related to lenacapavir as a long‑acting option for HIV prevention and treatment, as well as agreements affecting key products like Biktarvy, including patent settlements disclosed by the company.
Oncology and cell therapy news is another major theme. Through Kite, a Gilead company, GILD‑related releases feature data on Yescarta for relapsed or refractory large B‑cell lymphoma, next‑generation bicistronic CAR T‑cell candidates KITE‑753 and KITE‑363 for B‑cell lymphomas, and anitocabtagene autoleucel (anito‑cel) for relapsed or refractory multiple myeloma. Updates often include efficacy and safety results from pivotal and early‑stage trials, as well as details on collaborations such as the partnership with Arcellx on anito‑cel and the research collaboration with OncoNano Medicine on ON‑BOARD encapsulation technology.
Gilead news also reflects broader corporate and policy activity, including agreements with the U.S. government related to drug pricing and access, philanthropic grants from the Gilead Foundation for metastatic breast cancer support, leadership appointments, investor conference presentations and quarterly financial announcements. Bookmark this page to monitor how these scientific, commercial, governance and access‑related developments shape the ongoing story of GILD.
Gilead Sciences is set to release its third quarter 2020 financial results on October 28, after market close. A conference call will be held at 4:30 PM ET, where management will discuss the results and provide a business update. Investors can access the live webcast on the company's investor page or via phone. The results will be crucial for stakeholders to assess Gilead's performance, especially given its focus on innovative medicines for severe illnesses.
Gilead Sciences (Nasdaq: GILD) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its cash tender offer for Immunomedics, which expired on October 13, 2020. This marks a significant step towards the completion of the tender offer, which requires a majority of Immunomedics' outstanding shares to be tendered. The offer is set to expire on October 22, 2020. This development is crucial for Gilead as it seeks to enhance its product pipeline, particularly with Immunomedics' Trodelvy.
Gilead Sciences (GILD) and Galapagos presented late-breaking data on filgotinib during the UEGW Virtual Meeting. The Phase 2b/3 SELECTION trial results indicated that patients with moderately to severely active ulcerative colitis achieved higher clinical remission rates at Week 10 and sustained remission through Week 58 with filgotinib 200 mg compared to placebo. Key efficacy measures showed significant improvements, including corticosteroid-free remission. Safety profiles were comparable between filgotinib and placebo, with minimal adverse events reported.
The New England Journal of Medicine has published final results from the ACTT-1 trial of Gilead's Veklury (remdesivir) for hospitalized COVID-19 patients. The trial demonstrated that Veklury significantly reduced recovery time, showing a median recovery of 10 days versus 15 days for placebo. Patients who required oxygen benefited most, recovering seven days faster. The study also indicated a trend towards lower mortality rates. The trial met all primary and secondary endpoints, reinforcing Veklury's potential as a standard treatment for COVID-19 in hospitals.
Gilead Sciences announced positive long-term results for Biktarvy, a once-daily regimen for HIV treatment. In a study involving over 2,000 participants, 98% with preexisting drug resistance maintained virologic suppression without emerging resistance. An additional trial showed that older adults switching to Biktarvy maintained high suppression rates with minimal adverse events. The data reinforces Biktarvy's efficacy and safety profile, particularly for diverse patient needs, and aligns with Gilead's commitment to advancing HIV treatment.
Gilead has significantly ramped up production of its investigational antiviral drug, Veklury (remdesivir), since the onset of the COVID-19 pandemic. The company has made substantial investments to enhance manufacturing capacity and distributed 1.5 million vials for clinical evaluation. Starting October 1, Gilead will manage Veklury distribution in the U.S. through AmerisourceBergen, ensuring that hospitals can predictably order the drug. Clinical trials have shown Veklury's benefits for hospitalized COVID-19 patients, potentially improving recovery rates and reducing healthcare costs.
Gilead Sciences (Nasdaq: GILD) will present 13 studies at the upcoming HIV Glasgow 2020 conference, held virtually from October 5-8. These studies focus on the efficacy and safety of Biktarvy, a once-daily HIV treatment, as well as investigational long-acting therapy, lenacapavir. Gilead aims to address evolving needs in the HIV community, emphasizing patient-reported outcomes and the impact of COVID-19 on HIV care. The company is committed to scientific innovation and community support in advancing care for people living with HIV.